Infections With Enterohpatic Non-H. pylori Helicobacter Species in X-Linked Agammaglobulinemia: Clinical Cases and Review of the Literature

Carolina Romo-Gonzalez1, Juan Carlos Bustamante-Ogando2, Marco Antonio Yamazaki-Nakashimada2, Francisco Aviles-Jimenez4, Francisco Otero-Mendoza4, Francisco Javier Espinosa-Rosales6, Sara Elva Espinosa-Padilla2, Selma Cecilia Scheffler Mendoza3, Carola Durán-McKinster7, Maria Teresa García-Romero7, Mariar Saez-de-Ocariz7 and Gabriela Lopez-Herrera2*

1 Laboratory of Experimental Bacteriology, National Institute of Pediatrics, Mexico City, Mexico, 2 Immunodeficiency Research Unit, National Institute of Pediatrics, Mexico City, Mexico, 3 Clinical Immunology Service, National Institute of Pediatrics, Mexico City, Mexico, 4 Medical Unit in Infectious and Parasitic Diseases, High Speciality Medical Unit (UMAE) Pediatrics, National Medical Center (CMN) XXI Century, Mexican Social Security Institute (IMSS), Mexico City, Mexico, 5 Infectious Diseases Department, National Institute of Pediatrics, Mexico City, Mexico, 6 Immunology, Allergy and Pediatrics Center, Angeles Lomas Hospital, Mexico City, Mexico, 7 Dermatology Department, National Institute of Pediatrics, Mexico City, Mexico

The genus Helicobacter is classified into two main groups according to its habitat: gastric and enterohpatic. Patients with X-linked agammaglobulinemia (XLA) appear to be associated with invasive infection with enterohpatic non-Helicobacter pylori species (NHPH), mainly H. cinaedi and H. bilis. Such infections are difficult to control and have a high potential for recurrence. The spectrum of illnesses caused by these species includes recurrent fever, bacteremia, arthritis, osteomyelitis, cellulitis, abdominal abscesses, and pyoderma gangrenosum-like ulcer. The presence of these Helicobacters is particularly difficult to diagnose and eradicate, as they are very fastidious bacteria and present resistance to several types of antibiotics. We report two clinical cases of XLA patients infected with H. bilis. These infections were chronic in these patients and could not be eradicated in one of them. We also review the cases of enterohpatic non-Helicobacter pylori species (NHPH) in patients with this inborn error of immunity.

Keywords: non-H. pylori Helicobacters, H. bilis, H. cinaedi, X-linked Agammaglobulinemia, cellulitis, pyoderma gangrenosum-like, recurrent infections

INTRODUCTION

The genus Helicobacter includes species classified as gastric and enterohpatic. This genus belongs to a group of microaerophilic, gram-negative spiral-shaped bacteria. Among the gastric species, H. pylori is the most important, and its natural host is human; however, other Helicobacter species, both gastric and enterohpatic, have some animals as their natural host but can infect humans. Currently, several publications have shown the importance of both human and animal infection...
with the so-called non-\textit{Helicobacter pylori} \textit{Helicobacter} species (NHPH). Most clinically relevant enterohepatic NHPH are \textit{H. cinaedi} and \textit{H. bilis}, both of which colonize the intestine, biliary tree and liver of animals and humans. However, sporadic cases of \textit{H. fennelliae}, \textit{H. canis}, \textit{H. equorum}, \textit{H. canadiensis} and \textit{H. pollorum} have also been reported (Fox et al., 2000; Flahou et al., 2010; Shimizu et al., 2013; De Witte et al., 2016). The presence of \textit{H. cinaedi} and \textit{H. bilis}, which are considered the major enterohepatic NHPH associated with human diseases such as cellulitis, sepsis, osteomyelitis, and pyoderma gangrenosum (PG)-like ulcer, has been increasingly reported, particularly in immunocompromised hosts, including patients with X-linked agammaglobulinemia (XLA). However, other species have also been mentioned, such as \textit{H. equorum}, \textit{H. fennelliae}, and \textit{H. canadiensis} (Weir et al., 1999; Schwarze-Zander et al., 2010; Funato et al., 2011; Sharp, 2011), as well as \textit{Flexispira rappini}, a species proposed by Bryner et al., 1986. Later, in 2000, it was reported that \textit{F. rappini} strains represent at least 10 Helicobacter taxa, and in 2005, each taxon was considered a species of helicobacter. What was until now considered \textit{F. rappini} was demonstrated to be \textit{H. bilis} (Dewhirst et al., 2000; Hänninen et al., 2005; Kawamura et al., 2014).

XLA is an inborn error of immunity; patients with XLA have a severe reduction in all immunoglobulin isotypes and the number of peripheral B cells is less than 2% of non-affected controls. They suffer from recurrent bacterial infections frequently affecting the respiratory tract, particularly with encapsulated bacteria, and the treatment in these patients includes the administration of monthly intravenous or subcutaneous \(\gamma\)-globulin. XLA is caused by mutations in \textit{BTK} (Bruton’s tyrosine kinase), which encodes a crucial protein for B-cell development required for B-cell receptor (BCR) activation (López-Herrera et al., 2014). Several groups have reported infections with NHPH in XLA patients. Such infections are normally difficult to control, and unfortunately, international guidelines to treat these infections are not available.

Therapy with intravenous or subcutaneous \(\gamma\)-immunoglobulin efficiently reduces recurrent infectious diseases in patients with XLA and improves their quality of life (Durandy et al., 2005). However, some patients manifest aggressive infections with enterohepatic NHPH species and may progress to septicemia (Inoue et al., 2020). Enterohepatic NHPH species that show these types of infections include several species that are reviewed in this manuscript.

Most infections with enterohepatic NHPH species are initially detected in the skin. They are diagnosed initially as cellulitis and in some cases progress to PG-like ulcer (Harada et al., 2017). When these infections are not cleared despite antibiotic therapy, they progress to osteomyelitis and sepsis (Simons et al., 2004; Yoda et al., 2009). These infections are usually difficult to treat, as the infections are reported to have shown clinical resistance to several types of antibiotics (Cuccherini et al., 2000). For most of these infections, when resolved, broad-spectrum antibiotics are used, and it may require several months or even years of treatment to clear the infections. Here, we report two additional cases of NHPH infections and review the previous cases of NHPH reported by other authors.

**PATIENTS AND METHODS**

**Clinical Cases**

Case 1 and Case 2 were admitted to the National Institute of Pediatrics for their previous diagnosis of XLA and the presence of skin infections. Genetic diagnosis was performed for Case 2 and confirmed for Case 1; this case was previously reported to have an exon 11 deletion in cDNA (Lopez-Herrera et al., 2008), but it was not clear if it was due to a genomic deletion or due to a splice site mutation. In both cases, a biopsy from the infected skin was obtained to perform the bacterial identification, because no pathogenic bacteria could be isolated by culture. Both patients and their guardians gave their consent to provide the samples and participate in the studies reported here. Biopsies were also used for both hematoxylin-eosin and Warthin-Starry staining.

This study was approved by the ethics, research, and biosafety committees of the National Institute of Pediatrics, SSA, project numbers: 2017/010 and 2019/024. All procedures were conducted according to the 2013 Declaration of Helsinki.

**BTK Mutation Detection**

The BTK mutation in Case 1, as previously reported, is an exon 11 deletion in cDNA. To determine whether the deletion was due to a deletion in genomic DNA (gDNA) or a splice site mutation, gDNA was extracted from total blood using a Gentra Pure Gene Blood Kit (Qiagen, Hilden, Germany) and the patients were admitted to the National Institute of Pediatrics for their previous diagnosis of XLA and the presence of skin infections. Genetic diagnosis was performed for Case 2 and confirmed for Case 1; this case was previously reported to have an exon 11 deletion in cDNA (Lopez-Herrera et al., 2008), but it was not clear if it was due to a genomic deletion or due to a splice site mutation. In both cases, a biopsy from the infected skin was obtained to perform the bacterial identification, because no pathogenic bacteria could be isolated by culture. Both patients and their guardians gave their consent to provide the samples and participate in the studies reported here. Biopsies were also used for both hematoxylin-eosin and Warthin-Starry staining.

This study was approved by the ethics, research, and biosafety committees of the National Institute of Pediatrics, SSA, project numbers: 2017/010 and 2019/024. All procedures were conducted according to the 2013 Declaration of Helsinki.

**BTK Mutation Detection**

The BTK mutation in Case 1, as previously reported, is an exon 11 deletion in cDNA. To determine whether the deletion was due to a deletion in genomic DNA (gDNA) or a splice site mutation, gDNA was extracted from total blood using a Gentra Pure Gene Blood Kit (Qiagen, Hilden, Germany), and BTK exon 11 was amplified and sequenced using the following primer pairs: 5’ TGTAGCTCAAGCGTGACACTTG3’ and 5’ TCTGAGGTGGAACACAACAC3’. For Case 2, RNA was extracted from 3x10⁶ peripheral blood mononuclear cells using the TRIZol® method (Invitrogen, Waltham, Massachusetts, USA), and first strand cDNA synthesis was performed with SuperScript® III reverse transcriptase (Invitrogen) following the manufacturer’s instructions. For BTK amplification, the following oligonucleotide pairs were used: BTK-P1 (forward 5’TGAGAGTCCCAAGTCAAGT3’ and reverse 5’GGAATGCTTTTGATTAATAGCT3’), BTK-P2 (forward 5’TGTGGCTGCCAAGGACCTG3’ and reverse 5’TGCAGTGGAACGTTTCCTG3’), BTK-P3 (forward 5’ATTACCTGGCTGAAAGCAG3’ and reverse 5’AGCCCA AATGCTAGGGTGG3’), and BTK-P4 (forward 5’TGCGAGCTGGAAACTGTTTGG3’ and reverse 5’TTCCTTGG3’).
CCTTTGCTCAGAAG-3). PCRs were performed in a final volume of 25µl using Taq DNA polymerase (New England Biolabs, Ipswich, Massachusetts, USA), and the melting temperatures were 59°C for P1 and P3 and 57°C for P2 and P4, with an extension time of 60 seconds. PCR products were cleaned up with exonuclease I (Thermo Scientific, Waltham, Massachusetts, USA) and alkaline phosphatase (Promega, Madison, Wisconsin, USA) for 30 minutes at 37°C, and enzymes were inactivated at 80°C for 15 minutes. Finally, sequencing reactions were performed with BigDye v3.1® (Applied Biosystems, Waltham, Massachusetts, USA) and purified with BigDye Xterminator® (Applied Biosystems) following manufacturing instructions. Sequencing reactions were resolved in an ABI310 genetic analyzer (Applied Biosystems) and analyzed using 4peaks software (https://nucleobyt.com/4peaks) and the reference sequence ENST00000308731.8 from ensembl (www.ensembl.org).

DNA Extraction From Skin Biopsy Specimens
An incisional biopsy specimen was obtained from the affected skin of each patient. In Case 1, the biopsy specimen was harvested from the lesion in the right leg, and in Case 2, the biopsy specimen was harvested from the inner right leg. The biopsy samples were homogenized, and DNA was extracted from the homogenate. A total of 500 µL of the biopsy homogenate was incubated with 600 µL of buffer (10 mM Tris-HCl, pH 8.0 + 0.1% sarcosine) + 20 µL of Proteinase K (10 mg/mL) + 20 µL lysozyme (5 mg/mL) overnight at 50°C. The next day, proteinase K was inactivated by incubating at 95°C for 5 minutes. DNA extraction was carried out using the phenol-chloroform technique; DNA concentration and purity were calculated using the compound maximum probability method (Tamura et al., 2004).

NHPH Identification
H. cinaedi was identified by a nested PCR containing 2.0 µl of DNA template obtained from skin biopsies, 200 µM each of deoxynucleotide triphosphates (dATP, dCTP, dGTP, and dTTP), 1.25 U of DNA polymerase, and 0.25 µM of each primer (forward 5’GGAGCTGTGAGTGTGCTG3’ and reverse 5’AAATGACCGACACGAGCTG3’) in a final volume of 25 µl. The reaction conditions were 3 min denaturation at 95°C, followed by 35 cycles of 10 s of denaturing at 98°C, 30 s of annealing at 58°C, and 35 s of extension at 68°C. A final extension was at 68°C for 7 min. The PCR yielded a 659 bp product of the cdt gene that served as template for the second reaction using 1.0 µl of template and the set of internal primers (forward 5’GGATTTAGGCTCTGCTTCGTCCCGGATAT3’ and reverse 5’ATCACCCTCTTTACTCGCCG TCTCCCAAATTA3’). The conditions for the reaction were the same as those for the first reaction, and the final product was a fragment of 359 bp (Oyama et al., 2012).

For H. bilis identification, a specific PCR was performed in a final volume of 50 µL containing 5 µl of DNA obtained from skin biopsies, 0.5 µmol/L each of primers (HEBI-F1 5’-GGAAAAGGGCGTCTCTAAATAG-3’, and HEBI-R1 5’-GGCTGTGATCCTTAGCGAAG-3’), 200 µmol/L of each deoxynucleotide, 1.5 mmol/L MgCl2, and 1.25 U of GoTaq® Hot Start Polymerase in 1X colorless Flexi buffer (Promega, Madison, WI, USA). The amplification condition was 1 cycle at 94°C for 1 min, 55°C for 2 min, and 72°C for 3 min, followed by 39 cycles at 94°C for 45 s, 59°C for 1 min, and 72°C for 1 min, with a final extension at 72°C for 10 min. DNA from H. bilis strain ATCC 51630 was used as a positive control. The amplification produced a DNA fragment of 207 bp (Matsukura et al., 2002; Segura-López et al., 2015).

H. bilis Sequence Analysis
The genomic sequences were stored in a plain text file in fasta format. For sequence alignment, the BLAST program version 2.11.0 (local alignment program) for linux was used in command line mode [Scott et al., 2004]. Alignments were made between the fasta sequences of the samples and the bases of the bacterial genome data. The MEGA X program and the MUSCLE aligner were used with the UPGMA method. To view the alignments, we used the Jalview 2.11.1.4 program [Waterhouse et al., 2009]. Images of the multiple alignments were created, where the gaps, the alignment positions every 10 bases, and a consensus graph were marked with dashes. The sequences of the PCR products showed the highest alignment hit with the reported sequence NZ_JAERIZ010000077.1 Helicobacter bilis strain CCUG 38895. Relationships of the evolutionary history of the taxa were inferred using the UPGMA method. The evolutionary distances were calculated using the compound maximum probability method (Tamura et al., 2004).

RESULTS

Clinical Cases
It is important to describe that the skin biopsies taken were taken to perform the molecular identification of non-H. pylori species. In addition, they should mention here that whole blood samples were taken for the determination of mutations to diagnose X-linked agammaglobulinemia.

Case 1. An 18-year-old male diagnosed with X-linked agammaglobulinemia in 2008 (Lopez-Herrera et al., 2008), since then, he was on regular replacement therapy with IVIG. In March 2018 he presented mild erythematous macules in the right leg, he came to our center, and Helicobacter spp. infection was suspected. Skin biopsy showed an epidermis with dense inflammatory infiltrate composed of lymphocytes and neutrophils with marked spongiosis; dermis with abundant cell infiltrate (macrophages, lymphocytes, neutrophils, and some eosinophils), evidence of vasculitis; and the Warthin-Starry stain was positive, suggesting bacillary microorganisms (Figure 2). PCR showed positive amplification of the H. bilis genetic material. An MRI showed bone edema and incipient osteomyelitis in the opposite leg, suggesting hematogenous

Figure 1

Figure 2
dissemination. Due to an inflammatory infiltrate and the presence of PG-like ulcers, he received anti-inflammatory and immunosuppressive treatments (Supplementary Figure S1), but unfortunately, the lesion showed only mild improvement and then worsened again; we proposed hyperbaric oxygen therapy, but the patient did not consent. In March 2021, *P. aeruginosa* was isolated from the lesion surface, suggesting co-infection that was cleared after antibiotic treatment.

Case 2. A currently 11-year-old male presented with a history of cytopenia, recurrent pneumonia and sepsis, ecthyma, and hypogammaglobulinemia. He was diagnosed with X-linked agammaglobulinemia in 2014 and has received replacement therapy with human immunoglobulin regularly without severe infections since the diagnosis. The present episode started in December 2018 with a 10 x 5 cm ill-defined infiltrated erythematous plaque with scales and brownish crusts involving the right shin region extending to the lateral region of the same leg, resembling cellulitis (picture 1-a). Osteomyelitis was ruled out, but skin did not improve after treatment with anti-staphylococcal antibiotics. He was admitted to our center in January 2019, and a skin biopsy showed corneal laminar stratum with parakeratosis and orthokeratosis, some zones of hypergranulosis and psoriasiform acanthosis in the epidermis, dermis with intense cellular infiltrates (lymphocytes and histocytes), and notable lymphocytic infiltration of the subcutaneous tissue without evidence of virus, bacteria, fungi or mycobacteria. Tissue PCR identified positive genetic material for *H. bilis*. Treatment with amoxicillin plus clarithromycin, hyperbaric oxygen therapy, and local perilesional subcutaneous immunoglobulin showed clinical improvement, with lesion resolution and only residual hyperpigmentation after four weeks of treatment (Figure 3).

**BTK Mutations**

Case 1 was already reported to have a deletion of exon 11 in the BTK mRNA causing a premature stop codon in residue 321 (FSdGly299*321) (Lopez-Herrera et al., 2008). To determine whether the mutation was a deletion of the region around exon 11 or a splice change, exon 11 was ampli

FIGURE 2 | Hematoxylin-eosin (A) and Warthin-Starry (B) stainings showing a mixed inflammatory infiltrate from the skin biopsy from Case 1 and spiral-shaped bacilli among the infiltrates.
Presence of Enterohepatic NHPH in Biopsy of Skin

In both cases, the PCR for *H. cinaedi* was negative; however, a PCR product was amplified in the search for *H. bilis*. The 207 bp sequence derived from PCR was aligned, and analysis confirmed the presence of *H. bilis* (Figure 5). Comparative analysis of the 16S rRNA gene sequences of our Case 1 and Case 2 revealed an 8% sequence divergence between the two cases (p1 and p2).

The phylogenetic tree was constructed to show the relationship of the sequences of both cases with *H. bilis* sequences in GenBank (Figure 6). A small cluster closely linked Case 2 with strains ATCC 51630 and CCUG 38895.

Enterohpetic NHPH Infections in XLA

The literature review of patients with XLA and *Helicobacter sp* infections is summarized in Table 1. Of 21 cases, including the two new cases reported here, *H. cinaedi* was present in 8 cases and *H. bilis* in 8, one of which was co-infected with *H. canis*, and one case each for *H. fennelliae*, *H. equorum*, *H. canis* and *H. canadiensis*; in two cases, the species of *Helicobacter* was not identified (Table 1). Infections in these patients were frequently associated with cellulitis that progressed to sepsis and, in some cases, to PG-like ulcers or osteomyelitis. Cholangitis, abdominal abscess, and pleurisy was each reported in single cases (Table 1). Patients with these infections were treated for a few months to
several years, and most of the infections were resolved; however, in two cases, the authors mentioned slow healing of PG-like ulcers. In Case 1 reported here, PG-like ulcer did not resolve after long treatment with antibiotics.

Most of the species were identified by 16S sequencing or mass spectrometry of gDNA from biopsies or blood culture. Isolation on blood, chocolate or brucella blood agar in microaerophilic conditions with H₂ and/or CO₂ atmospheres was reported in 5 cases, but antibiotic resistance tests of the isolated bacteria were reported only in two cases. Cuccherini et al. reported resistance to trimethoprim/sulfamethoxazole, minocycline, rifampicin, nalidixic acid and cephalothin for an unspecified species of

FIGURE 5 | H. bilis identification in Cases 1 and 2. (A) PCR for Case 2 (1) Case 1 (2), negative control (3), molecular size marker (4), and positive control (5). (B) Sequence alignments of H. bilis 16S amplified from a control strain, Case 1, Case 2 and reference sequence from H. bilis CCUG 38895.

FIGURE 6 | Phylogenetic tree based on partial 16S rRNA sequences showing Case 1 and Case 2 = P1 and P2, respectively, within the radiation of H. bilis strains. Case 2 clusters with H. bilis strain CCUG38895 and control strain (ATCC 51630) used in the diagnosis. The numbers at the nodes indicate the level of bootstrap support (%) based on UPGMA method analyses of 500 bootstrap replications, and percentages are indicated on nodes. The scale bar indicates an 8.0% difference in gene sequence, and distances were computed with the maximum composite likelihood method.
| Helicobacter species | Identification | Type of infection | Resolved infection | Successful antibiotic treatment | Experimental or clinical resistance to antibiotics | Reference |
|----------------------|----------------|------------------|-------------------|-------------------------------|-----------------------------------------------|-----------|
| *Helicobacter*/*Flexispira*-like organism* | 16S sequencing of samples | Lower leg cellulitis | Yes | Imipenem and gentamicin. | Multiple courses of antibiotics for episodes of sepsis including ampicillin/ sulbactam, trimethoprim/sulfamethoxazole, ciprofloxacin, clindamycin, ceftriaxone, and rifampin. | (Weir et al., 1999) |
| *H. bilis* | Isolation of subcultures on blood agar from blood culture bottles. * | Leg cellulitis, sepsis | Yes, after 2 years | Imipenem, gentamicin, minocycline, metronidazole for 5 months. | Experimental resistance to trimethoprim/sulfamethoxazole, minocycline, and rifampin. | (Cuccherini et al., 2000) |
| *H. bilis* | Blood agar subcultures from blood culture bottles. * | Left knee Synovitis, skin ulcer at age 13, right leg pyoderma gangrenosum-like ulcer at age 17, osteomyelitis and sepsis at age 21 | Substantial improvement of lesion. | Imipenem, gentamicin, followed by IV meropenem, 9 months | Clinical recurrence with gentamicin/metronidazole, vancomycin, naldixic acid/cefalothin. | (Cuccherini et al., 2000) |
| *Helicobacter* sp. | 16S sequencing of pus samples | Left popliteal fossa tumor. Abdominal abscess on the left side of the abdominal wall. | Yes | Metronidazole and ciprofloxacin for 4 weeks. | N/S | (Han et al., 2000) |
| *H. canis* and *H. bilis* co-infection | 16S sequencing of subcultures on 5% sheep blood tryptic soy, blood and chocolate agar from blood culture bottles* | Cellulitis, sepsis | Yes | Doxycycline and metronidazole for 5 months | Clinical recurrence with benzypenicillin, amoxicillin, fluclaxacillin, diocxalexin and ceftriaxone, gentamicin, ampicillin, ciprofloxacin | (Gerrard et al., 2001) |
| *H. cinaedi* | 16S sequencing of samples from blood culture bottles | Left forearm and foot cellulitis, osteomyelitis, sepsis | Yes | IV gentamicin and imipenem for 6 weeks | Clinical recurrence with gatifloxacin IV and oral | (Simons et al., 2004) |
| *H. bilis* | Mass spectrometry of isolates on blood and chocolate agar from skin biopsy* | Arm and leg cellulitis, pyoderma gangrenosum-like ulcer | Yes | IV tobramycin and meropenem for 10 weeks | Clinical recurrence with amoxicillin/ clavulanate | (Murray et al., 2010) |
| *H. canadiensis like* | 16S sequencing of samples from blood culture bottles, Subculture on 5% blood Columbia agar, 5% blood Mueller-Hinton and chocolate agar* | Leg cellulitis, sepsis | Yes, slow healing | IV amoxicillin and gentamicin changed to IV imipenem, fosfomycin for 40 weeks. Maintenance with oral rifampicin and doxycycline | Experimental resistant to cephalothin, naldixic acid, ampicillin, azithromycin, clindamycin, ciprofloxacin and levofloxacin. Clinical resistance to ampicillin-sulbactam, ciprofloxacin, clindamycin, ceftazidime and clindamycin | (Schwarze-Zander et al., 2010) |
| *H. equorum-like* | 16S and 23S sequencing of pleural samples | Refractory chronic pleurisy | Yes | Piperacillin/betamipron at high doses and clindamycin | Clinical recurrence after macrolides, cephems, newquinolones, glycopeptides and carbapenems | (Funato et al., 2011) |
| *H. fennelliae* | 16S sequencing of bacteria on Brucella blood agar isolated from leg biopsy* | Leg pyoderma gangrenosum-like ulcer | N/S | N/S | N/S | (Sharp, 2011) |
| *H. cinaedi* | 16S sequencing of samples from leg biopsy | Leg pyoderma gangrenosum-like ulcer, synovitis | Yes | Doxycycline and ertapenem | N/S | (Oua et al., 2012) |
| *H. bilis* | PCR and 16S sequencing of samples | Leg cellulitis | Yes | Ertapenem (IV), azithromycin and clarithromycin, clindamycin and azithromycin | N/S | (Turvey et al., 2012) |

(Continued)
**TABLE 1 | Continued**

| Helicobacter species | Identification | Type of infection | Resolved infection | Successful antibiotic treatment | Experimental or clinical resistance to antibiotics | Reference |
|----------------------|---------------|------------------|--------------------|--------------------------------|-----------------------------------------------|-----------|
| H. cinaedi           | 16S PCR of samples from blood culture and mass spectrometry | Leg cellulitis, sepsis | Yes | Levofloxacin (oral) 12 months | Clinical recurrence and experimental resistance to ceftriaxone/ciprofloxacin, ampicillin/sulbactam, amoxicillin/clavulanic, kanamycin | (Degand et al., 2017) |
| H. cinaedi           | 16S PCR and mass spectrometry of samples from blood cultured bottles. | Hand and legs cellulitis | N/S | Minocycline. | Clinical recurrence after ampicillin/ sulbactam and amoxicillin. | (Sugimoto et al., 2017) |
| H. bilis            | 16S sequencing of samples from liver biopsy | Suppurative cholangitis | Yes | Parental ceftriaxone, metronidazole, oral doxycycline for 7 days. Oral moxifloxacin for 15 days and weekly IVG. Azithromycin for 2 months | Clinical resistance to ofloxacin and cefpodoxime. | (Degand et al., 2017) |
| H. cinaedi           | 16S sequencing of samples from biopsies. | Hyperpigmented plaques in both legs and subcutaneous nodules | Yes | Trimethoprim-sulfamethoxazole and doxycycline. | N/S | (Matsumoto et al., 2017) |
| H. cinaedi           | 16S sequencing of samples from blood culture bottles. | Erythematous plaques in the ankle | Yes | IV meropenem and oral doxycycline. | N/S | (Hill et al., 2018) |
| H. cinaedi           | Mass spectrometry and 16S PCR of samples from blood culture bottles. | Leg cellulitis, sepsis | Yes | IV imipenem/clastin (3w), oral minocycline (12w), combined with kanamycin (15d intestinal decontamination)? IV ceftriaxone, oral minocycline (2w), oral minocycline 18w. | Clinical recurrence after ceftriaxone and oral minocycline treatment | (Inoue et al., 2020) |
| H. cinaedi           | Mass spectrometry of samples from blood culture bottles. | Leg cellulitis, sepsis | Yes | IV ceftriaxone and oral minocycline | Clinical resistance to IV ceftriaxone and oral amoxicillin. | (Inoue et al., 2020) |
| H. bilis            | 16S sequencing of samples from leg biopsy. | Hand and leg cellulitis, Leg pyoderma gangrenosum-like ulcer | After two years of antibiotics treatment and anti-inflammatory treatment, no healing of lesion was appreciated | None | Clinical recurrence after clindamycin/ cefazidime, vancomycin/meropenem, amoxicillin/clavulanate, doxycycline, ceftepime, cefixime, meropenem/ amikacin, sulfamethoxazole, amoxicillin/ clarithromycin, metronidazole, levofloxacin, ciprofloxacin. | This report |
| H. bilis            | 16S sequencing of samples from leg biopsy. | Leg cellulitis | Yes | Amoxicillin/ clarithromycin | N/P | This report |

N/S, Not specified.
N/P, Not performed.
*Microaerophilic incubation with H2 and/or CO2 atmosphere.

**H. bilis**, (Cuccherini et al., 2000) and Schwarze-Zander reported resistance to ampicillin, azithromycin, clarithromycin, ciprofloxacin, and levofloxacin for their isolates of *H. canadiensis* (Schwarze-Zander et al., 2010). However, most of the cases showed clinical recurrence of the infection after several types of antibiotics were used to treat patients; *H. cinaedi* and *H. bilis/F. rappini* showed clinical recurrence after treatment with quinolones, penicillins, macrolides, cephaplorins, lincosamides and aminoglycosides (Cuccherini et al., 2000; Simons et al., 2004; Murray et al., 2010; Toyofuku et al., 2016; Sugimoto et al., 2017; Inoue et al., 2020). In other cases, *H. bilis/F. rappini* also showed recurrence after treatment with carbapenems, nitroimidazoles, sulfonamides/antifolates and tetracyclines (Cuccherini et al., 2000; Degand et al., 2017). Collectively, the antibiotics reported to help in clearing the infection were broad spectrum and included a combination of two or more antibiotics and were used in the following order of frequency: carbapenems, tetracyclines, aminoglycosides, macrolides, cephaplorins, nitroimidazoles, fluoroquinolones and antifolates (Table 1).

**DISCUSSION**

Immunodeficient patients with NHPH infections pose challenges for treatment, particularly due to the lack of information regarding bacterial pathogenicity, antibiotic resistance, and patient factors.
Infections with NHPH are usually reported in the lower extremities and, less frequently, in the upper extremities, suggesting that circulatory or other local factors (trauma) may play a role in the formation or persistence of the lesions caused by colonization with NHPH. In 19 out of 21 patients (90%), the legs were involved (Table 1). Patients with XLA are predisposed to a pro-inflammatory state, and they are prone to develop PG or PG-like lesions (González-Serrano et al., 2012; López-Herrera et al., 2014). The growing number of reports on XLA patients with NHPH-associated skin conditions ranging from cellulitis to PG-like lesions must be a sign to alert clinicians of possible colonization by NHPH and other fastidious bacteria and consider that such infections may perpetuate the local inflammatory response. Here, inflammatory infiltrate was observed in a biopsy from a lesion of Case 1. Additionally, staining for TNF-α was positive in PG lesions from other XLA patients, but NHPHs were not reported in these patients (Schwartzfarb et al., 2008). It is not fully clear to what extent these pathogens cause direct damage to the infected tissues or whether they trigger a continuous inflammatory response in patients with immunodeficiency contributing to tissue destruction. The answer to this question may have important clinical implications, as the treatments for infection and inflammatory disease are usually based on opposing principles (antibiotics vs. immunosuppression). In our patients, we believe that both factors played a role, and therefore, both antibiotics and immunomodulatory treatments were used. The two cases reported here showed contrasting clinical responses to treatment, despite both being confirmed XLA patients with BTK truncation mutations infected with H. bilis (Figure 3). Case 2 responded favorably to treatment with antibiotics, prednisone, and hyperbaric chambers; however, in Case 1, no improvement of the lesion was observed although different schemes were used to treat with antibiotics and immunosuppressive drugs. The use of immunosuppressive drugs was suspended for a period because we considered the possibility that they were exacerbating the progression of the infection. However, the patient condition did not improve when immunosuppressive treatment was withdrawn. Of note, when the treatment with prednisone was discontinued (Supplementary Figure S1), the patient immediately experienced worsening of symptoms such as local pain, paresthesia and difficulty walking. In the literature, different outcomes have also been reported for these NHPH soft tissue infections.

Species from the genus Helicobacter constitute a potential group of emerging pathogens in various hosts, ranging from humans to animals. At present, two groups of NHPHs are recognized based on their colonization site, classified as gastric and enterohepatic. H. cinaedi, H. bilis, and H. canis are enterohelial NHPHs that have been reported to be associated with human diseases such as bacteremia, cellulitis, cutaneous diseases, and fever of unknown origin in primary and secondary immunodeficiency. Apart from XLA, enterohepatic NHPH may also affect patients with acquired immunodeficiency syndrome (Husmann et al., 1994; Fleisch et al., 1998), patients with asplenia (Kim et al., 2012), and liver cirrhosis (Kamimura et al., 2015). In XLA, the source of the infections is unknown in most cases; however, it is suspected that they have a zoonotic origin (Owen, 1998; Schwarze-Zander et al., 2010) because many of the involved species are natural colonizers of dogs, cats, rodents, birds, pigs, sheep, and other animals (Owen, 1998). Many of the species associated with infections in humans have dogs, cats, rodents, birds, pigs, sheep, and other animals as natural hosts (Owen, 1998). Food-borne transmission has also been suggested; for example, Tee et al. reported H. pullorum gastroenteritis and bacteremia in immunocompetent patients who did not have previous contact with live chickens (Tee et al., 2001). Most of the cases reviewed here, including Case 1 and Case 2, showed skin infections, which are highly suggestive of zoonotic transmission after contact with infected animals; however, neither Case 1 nor Case 2 reported any contact with potential reservoirs for NHPH. Therefore, the absence of a clear epidemiological risk factor should not exclude the diagnosis in immunodeficient patients with NHPH skin infections.

Surprisingly, several reports indicate that enterohepatic NHPH species affecting XLA patients are highly resistant to treatment with several types of antibiotics, causing infection to remain for long periods of time (several years) and to affect other tissues. In contrast, in immunocompetent patients, enterohelial NHPH infections are easy to treat. One example is the report by Kitamura T et al., in which 11 immunocompetent patients, most of whom were over 70 years old, contracted H. cinaedi cellulitis or bacteremia after orthopedic surgery. In most cases, the infection was cleared after completing the antibiotic treatment that included penicillins and cephalosporins with few recurrences of infections. Of note, adaptive immune response in the elderly is not as robust as in younger patients, which is an important factor that could make these patients more vulnerable to enterohelial NHPH infections (Kitamura et al., 2007). Certainly, the immunological status of XLA patients contributes to the severity of enterohelial NHPH infections, but it is intriguing how other antibody deficiencies, such as common variable immunodeficiency, have not been associated with NHPH infections. This raises important questions about how the patient’s vulnerability and the bacterial virulence factors interact to establish such chronic and devastating infections of enterohelial NHPH species.

The resistance to multiple antibiotics shown by the enterohelial NHPH species has been poorly studied. This is primarily due to the difficulty of isolating these microorganisms. Testerman et al. reported the successful growth of H. pylori and some NHPH species in Ham’s F-12 medium supplemented with serum and iron and incubated in specific microaerophilic conditions of CO2 and O2 (Testerman et al., 2006). However, there were no positive subcultures of H. cinaedi and H. bilis, which are the most frequent species reported in XLA and other immunodeficient patients. For this reason, it is important to focus on the culture requirements and antibiotic susceptibility of these species, which may help in the treatment of these opportunistic bacteria.
Pathogenesis mechanisms are also unknown for most enterohepatic NHPH species. Most of the patients in Table 1, including Cases 1 and 2 reported in this manuscript, showed skin infections started as cellulitis and progressed to other tissues. The susceptibility of XLA patients to enterohepatic NHPH infection appears to be related to the fact that XLA is associated with severe B cell (humoral) immunodeficiency; thus, these patients have difficulty with clearing intravascular or intralymphatic infection (Cucherini et al., 2000).

Nothing is known about the bacterial mechanisms that compromise skin integrity to establish infection, colonize, stay in place and cause damage. The genomic sequence comparison between H. pylori and NHPH (Cao et al., 2016) as well as between gastric and enterohepatic NHPH species (Mannion et al., 2018) have shown regions into the genome unique to H. pylori but absent in NHPH and vice versa; a list of genes and outcomes comparing gastric and enterohepatic NHPH (shared genes and those unique to enterohepatic NHPH) may be useful in understanding mechanistic basis of its pathogenicity and adaptability.

In H. pylori, some of the strains that express virulence factors such as the pathogenicity island cagA are considered more virulent than others (Yamaoka, 2010). Similar mechanisms may be operational within the strains of H. bilis and H. cinaedi and account for differences in their ability to damage host tissues or their responses to treatment. Conversely, these strains may carry genes associated with resistance to antibiotics or types of immune responses characteristic to this group of Helicobacters. There are areas that need to be thoroughly investigated.

This is the first report in México on two cases of XLA and the presence of enterohepatic NHPH. H. bilis was the cause of chronic infections in both cases and is notoriously difficult to diagnose and eradicate. Based on the small number of publications worldwide, we highlight the typical features of H. bilis infection in XLA and provide a rational and successful approach to the diagnosis and treatment of this challenging infection.

In summary, clinical recommendations learned from the cases reported here and a review of the literature underscore several features that are consistently found in XLA patients infected with H. bilis:

Case 1 and Case 2 received different antibiotic regimens covering usual microorganisms causing cellulitis (for example, S. aureus and S. pyogenes), which may have played a role in generating resistance to antibiotics in NHPHs, apart from several virulence factors that a strain of H. bilis may carry. Given that Helicobacter spp. is not commonly suspected as the cause of soft tissue infections in the clinics, it is conceivable that some of the patients with PG-like ulcers may have been colonized by these or other fastidious microorganisms that perpetuate the local inflammatory response. Thus, when erythema or cellulitis is observed in XLA patients, NHPH infections should be suspected, and diagnosis using molecular techniques should be performed; otherwise, these microorganisms may not be detected. Such molecular methods are useful in identifying fastidious bacteria with special growth requirements. 16S rRNA gene sequencing should be used as the diagnostic method in XLA for timely identification of the bacteria. Additionally, we recommend performing a skin biopsy in these patients before starting treatments because histopathological findings may help to better understand the inflammatory response, to determine the existence of bacteria in the lesions, to guide some immunologically directed therapies, and to better understand the infection course and responses to treatment during the follow-up, especially in patients with poor outcomes.

The variability in treatment responses needs to be explored in more detail, as there may be factors related to microorganisms (species, virulence factors, antimicrobial resistance, etc.), to the host (nutritional status, geographic factors, age, gender, etc.), or to the health care context (delayed clinical suspicion and directed-treatment, lack of access to diagnostic methods or to broad-spectrum antibiotics, etc.). Case 2 responded well to antibiotics and hyperbaric oxygen therapy, while Case 1 did not receive the latter. There is evidence supporting beneficial effects of hyperbaric oxygen therapy in severe or refractory wounds in different scenarios, and this or other adjunctive treatments may be considered early in the course of Helicobacter spp. soft tissue infections. Additionally, clinicians should start treatment with antibiotics more likely to clear NHPH infections, such as carbapenems, tetracyclines, aminoglycosides, macrolides, cephalosporins, nitroimidazoles, fluoroquinolones and antiflates, and recognize that treatment may take several months. Therefore, antibiotics that may have serious side effects should be avoided.

CONCLUSION

The association of enterohepatic NHPH species with XLA is becoming more solid; however, there are still certain limitations in terms of the diagnosis and treatment to eradicate this infection. Enterohepatic NHPH infection should be suspected in XLA with fever and skin lesions, and molecular methods should be employed to provide timely and adequate treatment for patients.

In immunodeficient patients with NHPH infections, clinicians face an infectious disease that is not fully understood and lacks a standardized treatment. To provide an effective treatment, further research should be performed to isolate and study the pathogenicity factors that these bacteria might possess.

DATA AVAILABILITY STATEMENT

The data presented in the study are deposited in the GenBank repository, accession numbers: OM480733, OM480734, VCV001334133.1 and VCV0013359001.1.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by National Institute of Pediatrics Ethics Committee. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.
AUTHORS CONTRIBUTIONS

CR-G contributed to manuscript writing, performed the identification of NHPH in biopsy samples and analyzed the data. FA-J performed the identification of NHPH in biopsy samples, JB-O, MY-N, FE-R, FO-M, SE-P, SS-M, CD-M, MG-R, and MS-d-O contributed to manuscript writing and were involved in patient treatment and follow-up. GL-H performed the genetic studies to identify BTK mutations and directed the manuscript organization. All authors contributed to the article and approved the submitted version.

FUNDING

“Recursos Fiscales” from the National Institute of Pediatrics, Health Secretary, Mexico, supported this work (Project numbers: 2017/010 and 2019/024).

REFERENCES

Bryner, J. H., Littleton, J., Gates, C., Kirkbride, C. A., and Ritchie, A. E. (1986). *Flexispira Rappini* Gen. Nov., Sp. Nov., A Gram-Negative Rod From Mammalian Fetus And Feces; Microbe 86, abstract book of the XIV International Congress of Microbiology. Manchester, England p. 11–18.

Cao, D. M., Lu, Q. F., Li, S. B., Wang, J. P., Chen, Y. L., and Huang, Y. Q. (2016). Comparative Genomics of *H. pylori* and Non-*Pylori Helicobacter Species to Identify New Regions Associated With Its Pathogenicity and Adaptability. *Biomed. Res. Int.* 2016, 6106029. doi: 10.1155/2016/6106029

Cuccherini, B., Chua, K., Gill, V., Weir, S., Wray, B., Stewart, D., et al. (2000). Bacteremia and Skin/Bone Infections in Two Patients With X-Linked Agammaglobulinemia Caused by an Unusual Organism Related to *Flexispira/Helicobacter Species*. *Clin. Immunol.* 97, 121–129. doi: 10.1006/clim.2000.4932

Degand, N., Dautremer, J., Pilmis, B., Ferroni, A., Lanternier, F., Bruneau, J., et al. (2017). Helicobacter Bilis-Associated Suppurative Cholangitis in a Patient With X-Linked Agammaglobulinemia. *J. Clin. Immunol.* 37, 727–731. doi: 10.1007/s10875-017-0437-z

Dewhirst, F. E., Fox, J. G., Mendes, E. N., Paster, B. J., Gates, C. E., Kirkbride, C. A., De Witte, C., Schulz, C., Smet, A., Malfertheiner, P., and Haesebrouck, F. (2016). *Frontiers in Cellular and Infection Microbiology* | www.frontiersin.org February 2022 | Volume 11 | Article 807136

Elmer, J., Olsén, M., Melander, K., Mnier, C., Stenstrom, T., and Flavij, S. (2017). Identification and Characterization of Four New Helicobacter Species from a Patient With X-Linked Agammaglobulinemia. *J. Clin. Immunol.* 37, 50–5–1781

De Witte, C., Schulz, C., Smet, A., Malferttheiner, P., and Haesebrouck, F. (2016). Other Helicobacters and Gastric Microbiota. *Heliobacter* 21, 62–68. doi: 10.1111/hel.12243

Dua, J., Elliott, E., Bright, P., Grigoriadou, S., Hammer, M., et al. (2012). *Pyoderma Gangrenosum-Like Ulcer Caused by Helicobacter Cinaedi in a Patient With Hypogammaglobulinemia*. *J. Clin. Immunol.* 32, 742–745. doi: 10.1007/s10875-011-0429-x

Durandy, A., Wahn, V., Pettey, M., and Gelfand, E. W. (2005). Immunoglobulin Replacement Therapy in Primary Antibody Deficiency Diseases–Maximizing Success. *Int. Arch. Allergy Immunol.* 136, 217–229. doi: 10.1159/000083948

Flahou, B., Haesebrouck, F., Smet, A., Yonezawa, H., Osaki, T., and Kamiya, S. (2013). Gastric and Enteroheliotropic Non-Helicobacter Pylori Helicobacters. *Helicobacter* 18 Suppl 1, 66–72. doi: 10.1111/hel.12072

Fleisch, F., Burns, A., Weber, R., and Zbinden, R. (1998). Helicobacter Species Strain Main Isolated From Cultures of Blood From Two Patients With AIDS. *Clin. Infect. Dis.* 26, 526–527. doi: 10.1086/517110

Fox, J. G., Chien, C. C., Dewhirst, F. E., Paster, B. J., Shen, Z., Melito, P. L., et al. (2000). Helicobacter Canadensis Sp. Nov. Isolated From Humans With Diarrhea as an Example of an Emerging Pathogen. *J. Clin. Microbiol.* 38, 2546–2549. doi: 10.1128/JCM.38.7.2546-2549.2000

Funato, M., Kaneko, H., Ohkusu, K., Sasai, H., Kubota, K., Ohnishi, H., et al. (2011). Refractory Chronic Pleurisy Caused by Helicobacter Equorum-Like Bacterium in a Patient With X-Linked Agammaglobulinemia. *J. Clin. Microbiol.* 49, 3432–3435. doi: 10.1128/JCM.00478-11

ACKNOWLEDGMENTS

The authors acknowledge Violeta Larios and Karla Ruiz, Winter Genomics, Mexico City, Mexico for the sequence analysis and Gabriela Esquivel Jimenez for technical assistance. The authors thank the National Institute of Pediatrics for funding.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2021.807136/full#supplementary-material
Systemic Lupus Erythematosus. *Intern. Med.* 51, 3185–3188. doi: 10.2169/internalmedicine.51.8149
Kim, S. K., Cho, E. J., Sung, H., An, D., Park, S. J., Kim, M. N., et al. (2012). A Case of Helicobacter Cinaedi Bacteremia in an Asplenic Patient. *Ann. Lab. Med.* 32, 433–437. doi: 10.3343/alm.2012.32.6.433
Kitamura, T., Kawamura, Y., Ohkusu, K., Masaki, T., Iwashita, H., Sawa, T., et al. (2007). Helicobacter Cinaedi Cellulitis and Bacteremia in Immunocompetent Hosts After Orthopedic Surgery. *J. Clin. Microbiol.* 45, 31–38. doi: 10.1128/JCM.01507-06
Lopez-Herrera, G., Berron-Ruiuz, L., Mogica-Martinez, D., Espinosa-Rosas, F., and Santos-Argumondo, L. (2008). Characterization of Bruton’s Tyrosine Kinase Mutations in Mexican Patients With X-Linked Agammaglobulinemia. *Mol. Immunol.* 45, 1094–1098. doi: 10.1016/j.molimm.2007.07.022
Lopez-Herrera, G., Vargas-Hernandez, A., Gonzalez-Serrano, M. E., Berron-Ruiuz, L., Rodriguez-Alba, J. C., Espinosa-Rosas, F., et al. (2014). Bruton’s Tyrosine Kinase—An Integral Protein of B Cell Development That Also Has an Essential Role in the Innate Immune System. *J. Leukoc. Biol.* 95, 243–250. doi: 10.1189/jlb.0513307
Mannion, A., Shen, Z., and Fox, J. G. (2018). Comparative Genomics Analysis to Differentiate Metabolic and Virulence Gene Potential in Gastric Versus Enterohpetic Helicobacter Species. *BMIC Genomics* 19, 830. doi: 10.1186/s12864-018-5171-2
Matsukura, N., Yokomuro, S., Yamada, S., Tajiri, T., Sundo, T., Hadama, T., et al. (2010). Pyoderma Gangrenosum-Like Ulcer in a Patient With X-Linked Agammaglobulinemia. *Acta Dermat. Venereol.* 90, 165–170. doi: 10.2340/00015555-2501
Matsuzaki, Y., Yamazaki, H., Aida, Y., Ito, T., and Osada, Y. (2004). Characterization of Bruton’s Tyrosine Kinase Mutations in Japanese Patients With X-Linked Agammaglobulinemia. *Acta Derm. Venereol.* 84, 526–529. doi: 10.2340/00015555-9318
Murray, P. R., Jain, A., Uzel, G., Ranken, R., Ivy, C., Blyn, L. B., et al. (2010). Pyoderma Gangrenosum in a Patient With Bruton’s X-Linked Agammaglobulinemia. *JCM.01507-06
Nagata, T., Takahashi, H., Matsuyama, Y., and Okada, Y. (2006). Helicobacter Cinaedi Bacteremia Presenting as Macules in an Afebrile Patient With X-Linked Agammaglobulinemia. *Infection* 32, 367–370. doi: 10.1007/s10538-006-9012-6
Nakata, N., Miura, H., Kusuda, Y., and Kono, M. (2009). Pyoderma Gangrenosum-Like Ulcer in a Patient With X-Linked Agammaglobulinemia. *Acta Dermat.-Venereol.* 89, 365–367. doi: 10.2340/00015555-0911
Oyama, K., and Shikata, K. (2004). BLAST: At the Core of a Powerful and Diverse Set of Sequence Analysis Tools. *Nucleic Acids Res.* 32 (Web Server issue), W20–W25. doi: 10.1093/nar/gkh435
Segura-López, F. K., Avilés-Jiménez, F., Guirón-Cantú, A., Valdez-Salazar, H. A., León-Carballo, S., Guerrero-Pérez, L., et al. (2015). Infection With Helicobacter Bilis But Not Helicobacter Hepatisis Was Associated With Extrahepatic Cholangiocarcinoma. *Helicobacter* 20, 223–230. doi: 10.1111/hel.12195
Shimizu, S., Inokuma, D., Watanabe, M., Sakai, T., Yamamoto, S., Tsuchiya, K., et al. (2013). Cutaneous Manifestations of Helicobacter Cinaedi Infection. *Acta Dermato-Venereologica* 93, 165–167. doi: 10.2340/00015555-1396
Simons, E., Spacek, L. A., Lederman, H. M., and Winkelstein, J. A. (2004). Helicobacter Cinaedi Bacteremia Presenting as Macules in an Afebrile Patient With X-Linked Agammaglobulinemia. *Infection* 32, 367–368. doi: 10.1007/s10538-006-9012-6
Smet, A., and Menard, A. (2020). Review: Other Helicobacter Species. *Helicobacter* 25 (Suppl 1), e12744. doi: 10.1111/hel.12744
Testerman, T. L., Conn, P. B., Moley, H. L., and McGee, D. J. (2006). Nutritional Requirements and Antibiotic Resistance Patterns of Helicobacter Species in Chemically Defined Media. *J. Clin. Microbiol.* 44, 1650–1658. doi: 10.1128/JCM.44.5.1650-1658.2006
Toyofuku, M., Kim, S. K., Cho, E. J., Sung, H., An, D., Park, S. J., Kim, M. N., et al. (2012). A Case of Bruton’s Tyrosine Kinase Mutations in Mexican Patients With X-Linked Agammaglobulinemia. *Ann. Lab. Med.* 32, 165–170. doi: 10.3343/alm.2012.32.6.433
Turvey, S. E., Leo, S. H., Boos, A., Deans, G. D., Prendiville, J., Crawford, R. L., et al. (2012). Successful Approach to Treatment of Helicobacter Bilis Infection in X-Linked Agammaglobulinemia. *J. Clin. Immunol.* 32, 1400–1408. doi: 10.1007/s10875-012-9730-8
Waterhouse, A. M., Procter, J. B., Martin, D. M. A., Clamp, M., and Barton, G. J. (2009). Jalview Version 2 - A Multiple Sequence Alignment Editor and Analysis Workbench. *Bioinformatics* 25 (9), 1189–1191. doi: 10.1093/bioinformatics/btp033
Weir, S., Cuccherini, B., Whitney, A. M., Ray, M. L., MacGregor, J. P., Steigerwald, A., et al. (1999). Recurrent Bacteremia Caused by a “Flexispira”-Like Organism in a Patient With X-Linked Bruton’s Agammaglobulinemia. *J. Clin. Microbiol.* 37, 2439–2445. doi: 10.1128/JCM.37.8.2439-2445.1999
Yamazaki, T. S. (2006). Mutations in Mexican Patients With X-Linked Agammaglobulinemia. *Ann. Lab. Med.* 26, 389–390. doi: 10.1128/JCM.01652-12
Yoda, K., Ito, T., Matuda, Y., and Murotani, N. (2009). Isolation of Helicobacter Cinaedi From a Sepsis Patient With Cellulitis. *Ipn J. Infect. Dis.* 62, 169.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

---

*Copyright © 2022 Romo-Gonzalez, Bustamante-Ogando, Yamazaki-Nakashimada, Avilés-Jiménez, Otero-Mendoza, Espinoza-Rosas, Espinoza-Padilla, Scheffler Mendoza, Durán-McKinster, García-Romero, Saúz-de-Ovartz and Lopez-Herrera. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*